ImmunityBio, Inc. (NASDAQ: IBRX) announced that its innovative therapy Anktiva® (nogapendekin alfa inbakicept) in combination with BCG has been approved by the European Commission for the treatment of patients with carcinoma in situ (CIS) of non-muscle invasive bladder cancer (NMIBC).
Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
This authorization marks that the therapy has obtained marketing approval in 33 countries, including the 30 member states of the European Economic Area (EEA) as well as Iceland, Liechtenstein, and Norway, which will significantly enhance global patients' access to this cutting-edge treatment option.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now！
You may also like
Kashkari: Interest rates would need to be raised if inflation expectations become unanchored
AiCoin•2026/05/01 12:13
Trending news
MoreCrypto prices
More
Bitcoin
BTC
$78,458.07
-0.25%
Ethereum
ETH
$2,308.27
-0.18%
Tether USDt
USDT
$0.9998
-0.01%
XRP
XRP
$1.39
-0.37%
BNB
BNB
$618.26
-0.46%
USDC
USDC
$0.9998
-0.00%
Solana
SOL
$84.01
-0.60%
TRON
TRX
$0.3328
+2.08%
Dogecoin
DOGE
$0.1089
-0.31%
Hyperliquid
HYPE
$41.65
+1.53%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now